Septerna (SEPN) Shares Outstanding (Weighted Average) (2023 - 2026)
Septerna's quarterly Shares Outstanding (Weighted Average) came in at $44.8 million in Q1 2026, up 1.87% year-on-year from $43.9 million in Q1 2025, and up 1.13% quarter-over-quarter from $44.3 million in Q4 2025.
Septerna has reported Shares Outstanding (Weighted Average) for 4 years, with the latest figure at $44.8 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 1.87% year-over-year to $44.8 million; the trailing twelve-month figure through Mar 2026 stood at $44.8 million (up 1.87% YoY), and the FY2025 full-year result was $44.3 million, up 347.46% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $44.8 million, up from $44.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $44.8 million in Q1 2026, with the low at $1.9 million in Q4 2023.
- Average Shares Outstanding (Weighted Average) over 4 years is $22.0 million, with a median of $9.9 million recorded in 2024.
- Year-over-year, Shares Outstanding (Weighted Average) jumped 1868.31% in 2025 and climbed 1.87% in 2026.
- Tracing SEPN's Shares Outstanding (Weighted Average) over 4 years: stood at $1.9 million in 2023, then soared by 412.87% to $9.9 million in 2024, then surged by 347.46% to $44.3 million in 2025, then gained by 1.13% to $44.8 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $44.8 million (Q1 2026), $44.3 million (Q4 2025), and $44.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | 44.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.76 Mn |
| Dec 31, 2025 | 44.26 Mn |
| Sep 30, 2025 | 44.34 Mn |
| Jun 30, 2025 | 44.05 Mn |
| Mar 31, 2025 | 43.94 Mn |
| Dec 31, 2024 | 9.89 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 2.28 Mn |
| Mar 31, 2024 | 2.23 Mn |
| Dec 31, 2023 | 1.93 Mn |
| Sep 30, 2023 | 2.01 Mn |